TAGS Pinterest By Digital AIM Web Support – March 23, 2021 Twitter WhatsApp Facebook DUBLIN–(BUSINESS WIRE)–Feb 8, 2021– The “Cell Therapy Market by Cell Type, Therapy Type, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2020-2027” report has been added to ResearchAndMarkets.com’s offering. The global cell therapy market accounted for $7,754. 89 million in 2019, and is expected to reach $48,115. 40 million by 2027, registering a CAGR of 25. 6% from 2020 to 2027. Cell therapy involves administration of somatic cell preparations for treatment of diseases or traumatic damages. Cell therapy aims to introduce new, healthy cells into a patient’s body to replace diseased or missing ones. This is attributed to the fact that specialized cells, such as brain cells, are difficult to obtain from human body. In addition, specialized cells typically have a limited ability to multiply, making it difficult to produce sufficient number of cells required for certain cell therapies. Some of these issues can be overcome through the use of stem cells. In addition, cells such as blood and bone marrow cells, mature, immature & solid tissue cells, adult stem cells, and embryonic stem cells are widely used in cell therapy procedures. Moreover, transplanted cells including induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and mesenchymal stem cells (MSCs) are divided broadly into two main groups including autologous cells and non-autologous cells. Development of precision medicine and advancements in Advanced Therapies Medicinal Products (ATMPS) in context to their efficiency and manufacturing are expected to be the major drivers for the market. Furthermore, automation in adult stem cells and cord blood processing and storage are the key technological advancements that fuel growth of the market for cell therapy. In addition, growth in aging patient population, The rise in cell therapy transplantations globally, and surge in disease awareness drive growth of the global cell therapy market. Furthermore, The rise in adoption of human cells over animal cells for cell therapeutics research, technological advancements in field of cell therapy, and increase in incidences of diseases such as cancer, cardiac abnormalities, and organ failure are the key factors that drive growth of the global market. Moreover, implementation of stringent government regulations regarding the use of cell therapy is anticipated to restrict growth of the market. On the contrary, surge in number of regulations to promote stem cell therapy and increase in funds for research in developing countries are expected to offer lucrative opportunities to the market in the future. The global cell therapy market is categorized on the basis of therapy type, therapeutic area, cell type, end user, and region. On the basis of therapy type, the market is segregated into autologous and allogenic. By therapeutics, it is classified into malignancies, musculoskeletal disorders, autoimmune disorders, dermatology, and others. Key BenefitsThe study provides an in-depth analysis of the global cell therapy market along with the current trends and future estimations to elucidate the imminent investment pockets.Comprehensive analysis of factors that drive and restrict the market growth is provided in the report.Comprehensive quantitative analysis of the industry from 2019 to 2027 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.Extensive analysis of the key segments of the industry helps in understanding the forms and types of cell therapy used across the globe.Key market players and their strategies have been analyzed to understand the competitive outlook of the market. Market Dynamics DriversTechnological Advancements in the Field of Cell TherapyThe Rise in Number of Cell Therapy Clinical StudiesThe Rise in Adoption of Regenerative Medicine RestraintDeveloping Stage and Pricing OpportunityHigh Growth Potential in Emerging Markets Companies ProfiledAllosourceCells for CellsHolostem Terapie Avanzate SrlJcr Pharmaceuticals Co. Ltd.Kolon Tissuegene, Inc.Medipost Co. Ltd.Mesoblast LtdNuvasive, Inc.Osiris Therapeutics, Inc.Stemedica Cell Technologies, Inc. For more information about this report visit https://www.researchandmarkets.com/r/qwjn6g View source version on businesswire.com:https://www.businesswire.com/news/home/20210208005698/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH GENERAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/08/2021 12:53 PM/DISC: 02/08/2021 12:53 PM http://www.businesswire.com/news/home/20210208005698/en Twitter Global Cell Therapy Market (2020 to 2027) – by Cell Type, Therapy Type, Therapeutic Area, and End-user – ResearchAndMarkets.com Local NewsBusiness Pinterest Facebook WhatsApp Previous articleKami Hoss, DDS of The Super Dentists Launches Super Toothbrushes for Kids – Infants to TeensNext articleTrump’s 2nd trial to start with fight over its legitimacy Digital AIM Web Support
1SHARESShareShareSharePrintMailGooglePinterestDiggRedditStumbleuponDeliciousBufferTumblr Former Mississippi State Senator Tommy Robertson, a former attorney for the board of directors of the $194 million Singing River Federal Credit Union, pleaded guilty in Jackson County Circuit Court Monday to embezzling more than $375,000 from the Moss Point, Miss.-based cooperative.Robertson’s case was turned over to the Mississippi Department of Corrections’ Probation and Parole Office to conduct a presentencing report, according to Willa Witchen, deputy Clerk of Courts for Jackson County Circuit Court in Pascagoula. continue reading »
Pogba had also added to the doubts surrounding his future by saying that “all players dream of playing for Real Madrid”.But ahead of his team’s La Liga game at home to Villarreal on Sunday, Zidane appeared to downplay the chances of Pogba moving to the Santiago Bernabeu.“I said Pogba was a good player but I could say the same about other players,” Zidane said at a press conference on Saturday.“I know him but nothing more. If you ask me about Pogba, I say he is a very good player but he plays for Manchester United.“At the end of the season we will see which players come here, and who leaves, but I did not say ‘We are going to sign Pogba,’ nothing like that.“I will not say anything until the deals are done.”Madrid sit third in La Liga, 18 points behind champions Barcelona and with little hope of catching Atletico Madrid in second.Zidane’s team have delivered a series of underwhelming performances, most recently in a 0-0 draw with Getafe and 1-0 defeat to Rayo Vallecano.“I was very angry the other day, so were the players, they didn’t enjoy it either,” Zidane said. “Sometimes nothing goes your way.”Madrid fans have vented their frustration towards a number of players, in particular Gareth Bale, but Zidane said supporters cannot assume anyone will leave.“The season is what it is but the fans must think about next season. There will be changes but many of these players will stay,” he said.“The fans will be the same, and most of the players too so we must stick together.“We are going to have time to prepare for next season. Until August 31 anything can happen, so it will be a long summer.”Vinicius Junior has been one of the few positives to come from Madrid’s season and he could return against Villarreal after two months out with a hamstring injury.“Vinicius is training much better and ready to be in the squad,” Zidane said.“He is very good, he is an important player for this team and the future. He is 18 years old and we have to be patient.“But he deserves to be here and next year, we will see how we can make the best of him.”0Shares0000(Visited 1 times, 1 visits today) 0Shares0000Real Madrid head coach Zinedine Zidane has played down reports linking Manchester United’s French midfielder Paul Pogba with a move to the Spanish club © AFP/File / Paul ELLISMADRID, Spain, May 4 – Zinedine Zidane has played down speculation linking Real Madrid with a summer move for Manchester United midfielder Paul Pogba.Zidane said in March he knew Pogba personally and likes him “a lot” before adding Madrid could be his next club “when his experience in Manchester comes to an end”.
Finn Harps have completed the signing of full-back JP Gallagher from Irish League side Dungannon Swifts.JP, 28, from Strabane, also played with Irish League double winners Linfield, whom he left to join Dungannon last January.Finn Harps would like to place on record their thanks to JP’s employers, PK Wholesales from Strabane, for allowing the player leave to link up with the squad on matchdays. Harps remain rooted to the bottom of the First Division after the first seris of matches in the league.EndsHARPS SWOOP FOR SWIFTS’ JP GALLAGHER was last modified: May 17th, 2011 by StephenShare this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window)